CONFERENCES

      Respiratory Drug Delivery Europe Conference

      Respiratory Drug Delivery Europe (RDD) is an annual conference focusing on the development and commercialization of pulmonary and nasal pharmaceutical products, with topics ranging from new drug delivery technologies to regulatory issues. The event is aimed at bringing together scientists, academics, researchers, healthcare professionals, regulators, and industry experts, and provides a forum for sharing knowledge and collaborating to identify the latest advances in respiratory drug delivery.

      Respiratory Drug Delivery Europe RDD 2019

      Date

      May 07, 2019 - May 10, 2019

      Location

      Lisbon, Portugal

      Attracting over 500 delegates from over 30 countries, this event is the largest RDD Europe conference with about 85% of attendees reporting working for pharmaceutical companies or their suppliers while the remaining 15% are from academia and regulatory authorities.

      See related posters

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.